HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Tan Sheet

Executive Summary

FTC/Garden of Life case continues; FDA deems ForMor in violation of GMPs; Kanebo faulted for pharmaceutical GMP failures; CytoSport settles litigation over Muscle Milk labeling; USPlabs’ carb claim canned in NAD review; FDA extends comment time on FSMA tracking pilots.

You may also be interested in...



In Brief

CDER clarifies toll-free number labeling; FTC consent decree edit fails in Garden of Life case; NAD rules on Ranir’s Abridge ad; POM Wonderful, FTC plot appeals of ALJ decision; more news In Brief.

In Brief

Nestle takes stake in constipation cure firm

HIV/AIDS, Cancer Cure Supplement Claims Targeted In Six FTC Actions

Western Dietary Products will preliminarily halt Internet marketing claims that its black walnut, wormwood and clove tinctures treat and cure diseases such as cancer, diabetes and HIV/AIDS, the Federal Trade Commission says.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel